Biodesix (NASDAQ:BDSX) Share Price Crosses Below 200-Day Moving Average - Should You Sell?

Key Points

• Biodesix shares fell sharply, trading at $8.53 after dipping to $7.96 and crossing below the 200-day moving average of $18.90.
• Third-quarter revenue was $24.04 million, below the $27.49 million analyst estimate; the company’s loss of $0.75 per share matched consensus.
• Biodesix forecast 2026 revenue of $101 million to $103 million, below the $111.7 million analyst consensus, while planning to end the year with about 115 sales representatives.

Biodesix, Inc. (NASDAQ:BDSX - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $18.90 and traded as low as $7.96. Biodesix shares last traded at $8.53, with a volume of 1,586,239 shares changing hands.

Biodesix News Summary

Here are the key news stories impacting Biodesix this week:

• Neutral Sentiment: Biodesix plans to end 2026 with approximately 115 sales representatives, an effort to expand its commercial reach. Article
• Negative Sentiment: Third-quarter revenue was $24.04 million, below analysts’ estimate of $27.49 million. Biodesix reported a loss of $0.75 per share; one cited consensus was $0.75, while Zacks reported a $0.74 estimate. Article
• Negative Sentiment: For 2026, the company forecast revenue of $101 million to $103 million, below the $111.7 million analyst consensus—signaling a weaker outlook than investors had expected. Article
• Negative Sentiment: Biodesix disclosed the departure of Chief Commercial Officer Ki…; the leadership change may add uncertainty as the company works to grow sales. Article
• Negative Sentiment: Following the sharp decline, Johnson Fistel said it had opened an investigation into whether Biodesix or its officers made misleading statements or failed to disclose material information. This is an investigation, not a finding of wrongdoing. Article

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Weiss Ratings raised Biodesix from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, September 8th. Canaccord Genuity Group upped their price objective on Biodesix from $27.00 to $35.00 and gave the stock a "buy" rating in a report on Monday, August 10th. TD Cowen reissued a "buy" rating and issued a $40.00 price objective (up from $30.00) on shares of Biodesix in a report on Tuesday, October 13th. Finally, HC Wainwright reissued a "buy" rating on shares of Biodesix in a report on Thursday, October 22nd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $36.25.

Biodesix Trading Down 57.0%

The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 5.12. The stock has a market capitalization of $89.99 million, a price-to-earnings ratio of -3.09 and a beta of 0.65. The company's 50-day moving average is $25.53 and its 200-day moving average is $18.90.

Biodesix (NASDAQ:BDSX - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.75) EPS for the quarter, hitting the consensus estimate of ($0.75). Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. The firm had revenue of $24.04 million for the quarter, compared to analyst estimates of $27.49 million. Research analysts anticipate that Biodesix, Inc. will post -2.68 earnings per share for the current fiscal year.

Insider Activity at Biodesix

In other news, Director Jack Schuler bought 15,000 shares of the stock in a transaction on Wednesday, August 12th. The shares were purchased at an average price of $24.47 per share, for a total transaction of $367,050.00. Following the completion of the purchase, the director directly owned 555,810 shares of the company's stock, valued at $13,600,670.70. This trade represents a 2.77% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have bought 42,600 shares of company stock valued at $1,033,062 in the last ninety days. Company insiders own 23.20% of the company's stock.

Institutional Investors Weigh In On Biodesix

A number of institutional investors and hedge funds have recently made changes to their positions in BDSX. AIGH Capital Management LLC increased its holdings in shares of Biodesix by 1.1% in the third quarter. AIGH Capital Management LLC now owns 686,021 shares of the company's stock worth $20,464,000 after acquiring an additional 7,693 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Biodesix during the second quarter worth approximately $1,679,000. Stempoint Capital LP bought a new position in Biodesix during the first quarter worth about $1,015,000. GSA Capital Partners LLP acquired a new stake in shares of Biodesix during the 2nd quarter worth $1,060,000. Finally, BlackRock Inc. bought a new stake in Biodesix during the second quarter worth $970,000. Institutional investors own 20.96% of the company's stock.

Biodesix Company Profile

Biodesix, Inc is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions.

Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.